These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10564892)

  • 21. Spironolactone for heart failure: a worthy addition to therapy.
    Rittenhouse SK
    Adv Nurse Pract; 2001 Jan; 9(1):34-6, 39. PubMed ID: 12416036
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug therapy in chronic heart failure.
    Jolobe O
    Postgrad Med J; 2004 Apr; 80(942):247. PubMed ID: 15082857
    [No Abstract]   [Full Text] [Related]  

  • 25. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
    Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A
    Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Just the berries. Management of heart failure.
    Ruggles L
    Can Fam Physician; 2001 Mar; 47():499-501. PubMed ID: 11281082
    [No Abstract]   [Full Text] [Related]  

  • 28. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmacological treatment of chronic heart failure in patients with renal failure].
    Stawicki S; Starczewska MH; Roik M; Opolski G
    Kardiol Pol; 2005 Mar; 62(3):254-60. PubMed ID: 15830021
    [No Abstract]   [Full Text] [Related]  

  • 30. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 31. [The process of drug development. The "case" of spironolactone].
    De Feo S; Opasich C; Volpi A; Tavazzi L
    Ital Heart J Suppl; 2002 Feb; 3(2):178-86. PubMed ID: 11926024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of aldosterone block in combined therapy of heart failure].
    Arutiunov GP; Rylova AK
    Ter Arkh; 1999; 71(12):72-4. PubMed ID: 10647211
    [No Abstract]   [Full Text] [Related]  

  • 33. Heart failure: recent advances in prevention and treatment.
    Fonarow GC
    Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spironolactone in heart failure--a revived role for an old drug.
    Bradley C
    Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-aldosterone: the evidence of the RALES study].
    Zannad F
    Arch Mal Coeur Vaiss; 2000 Jun; Spec No():8-9, 15. PubMed ID: 10949699
    [No Abstract]   [Full Text] [Related]  

  • 37. Spironolactone and ACE inhibition in chronic renal failure.
    Almirall J; Lopez T
    N Engl J Med; 2002 Feb; 346(6):456-7. PubMed ID: 11837270
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacotherapeutic strategy in heart failure.
    Dominiak P
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S2-6. PubMed ID: 12227721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
    Jotkowitz AB; Porath A; Shotan A; Mittelman M; Grossman E; Zimlichman R; Lewis BS; Caspi A; Gottlieb S; Garty M;
    Isr Med Assoc J; 2006 Dec; 8(12):875-9. PubMed ID: 17214110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.